Sermorelin (10mg)

A single-component research material supplied for controlled research environments. Suitable for studies involving GHRH-receptor pathway characterization and method development in model systems.

Composition

• Sermorelin: 10 mg

• Appearance: lyophilized powder in a sealed research vial

Research Focus (non-clinical)

• Peptide identity and purity assessment

• Assay development and calibration for quantitative analysis

• Chromatographic method optimization for impurity profiling and peak resolution

• Stability characterization of a lyophilized peptide under laboratory storage conditions

Documentation

• Lot-specific COA available

• Batch and lot traceability

Important Notice

• For research use only

• Not for human consumption

• Not intended to diagnose, treat, cure, or prevent any disease

Quality & Manufacturing

• Lot-specific COA

• Lyophilized for transit stability; batch traceable

• Tamper-evident seal; lot & test date on each vial

• No MOQ for online orders

• Bulk orders for physical locations start at 25-unit minimum

What It Is

Sermorelin (GHRH 1-29) is a synthetic 29-amino-acid peptide corresponding to the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH), and represents the shortest such fragment reported to retain the full biological activity of the native 44-amino-acid hypothalamic peptide.

Research Background

Sermorelin has been examined across clinical, animal, and in vitro research contexts. Clinical investigations have studied its administration in healthy adult male subjects and in prepubertal children, characterizing dose-response relationships and pharmacokinetic profiles following intravenous and subcutaneous delivery. Animal model research has employed the dwarf little mouse — which harbors a loss-of-function mutation in the GHRH receptor — as well as GHRH-overexpressing transgenic mice, to investigate the receptor's role in somatotroph cell biology. In vitro studies using pituitary cell preparations have further characterized the receptor-mediated signaling cascades engaged by GHRH and its analogues, including GHRH(1-29).

Observed Areas of Interest in Research

Research has focused on the interaction of sermorelin/GHRH(1-29) with the growth hormone-releasing hormone receptor (GHRH-R), a class B G protein-coupled receptor characterized by seven transmembrane helices expressed predominantly on pituitary somatotroph cells. Studies have examined how GHRH-R activation stimulates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP) concentrations and triggering downstream protein kinase A (PKA) signaling, including phosphorylation of the transcription factor CREB and subsequent effects on GH gene expression and somatotroph cell proliferation. Researchers have additionally investigated MAP kinase pathway activation and ERK phosphorylation in pituitary somatotroph cells, as well as phospholipase C (IP3/DAG) pathway engagement following GHRH-R stimulation. Animal studies have used somatotroph hypoplasia (dwarf mouse) and hyperplasia (GHRH-overexpressing transgenic mouse) models to probe the receptor's developmental role in pituitary cell biology.

Research Notes

Purity verified by third-party laboratory analysis (Certificate of Analysis available on request). Supplied strictly for in-vitro and laboratory research use only. Not for human consumption.

All information above is provided for research and educational reference only and summarizes findings from published scientific literature (predominantly in-vitro and animal models). It does not describe outcomes in humans. This product is not a drug, dietary supplement, or article intended for human or veterinary use.

All products from Blitz Health are manufactured using a lyophilization (freeze-drying) process. This method is designed to maintain product integrity and allows vials to remain stable during shipping for approximately 3–4 months.

Once a vial is reconstituted with bacteriostatic water, it should be stored in the refrigerator to help maintain stability. Under these conditions, reconstituted material is generally considered stable for up to 30 days.

Lyophilization is a dehydration technique in which compounds are frozen and then exposed to low pressure. This causes the water in the vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure. This powder can be kept at room temperature until reconstitution.

Upon receipt, products should be stored away from heat and light. For short-term use, refrigeration at approximately 4°C (39°F) is suitable. For long-term storage (several months to years), vials may be placed in a freezer at approximately -80°C (-112°F). Freezing is the preferred method for preserving product stability over extended periods.

⚠️ Important Notice:
These products are intended for research use only. Not for human consumption.